Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition

American Journal of Hematology

Volumn 88, Issue 5, 2013, Pages 385-393

  Simara, Pavel ^a   Stejskal, Stanislav ^a   Koutna, Irena ^a   Potesil, David ^a   Tesarova, Lenka ^a   Potesilova, Michaela ^a   Zdrahal, Zbynek ^a   Mayer, Jiri ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CRK LIKE PROTEIN; DASATINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; STAT5 PROTEIN;

APOPTOSIS; ARTICLE; CELLS; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG RETENTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; STEM CELL; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BIOLOGICAL TRANSPORT; BONE MARROW CELLS; CELL LINE, TUMOR; FUSION PROTEINS, BCR-ABL; HUMANS; KINETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; OSMOLAR CONCENTRATION; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIMIDINES; THIAZOLES; TUMOR CELLS, CULTURED;

EID: 84876706845     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23419     Document Type: Article

References (34)

1. Rowley J. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-293.
2. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-830.
3. Druker B. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112:4808-4817.
4. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-6051.
5. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004;22:935-942.
6. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879-894.
7. Shah N, Tran C, Lee F, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
8. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26:2197-2203.
9. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-Year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123-1129.
10. Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008;14:352-359.
11. Shah N, Kasap C, Weier C, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008;14:485-493.
12. Shah N, Kantarjian H, Kim D, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-3212.
13. Talpaz M, Shah N, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-2541.
14. Snead JL, O'Hare T, Adrian LT, et al. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 2009;114:3459-3463.
15. Hiwase DK, White DL, Saunders VA, et al. Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells. Leukemia 2009;23:1205-1206.
16. Nichols G, Raines M, Vera J, et al. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994;84:2912-2918.
17. Patel H, Marley S, Gordon M. Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2. Genes Chromosomes Cancer 2006;45:1121-1129.
18. White D, Saunders V, Lyons A, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005;106:2520-2526.
19. Hamilton A, Elrick L, Myssina S, et al. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia 2006;20:1035-1039.
20. Simara P, Peterkova M, Stejskal S, et al. BCR-ABL activity measured by the IC50(imatinib), p-CrkL/CrkL ratio, or p-CrkL ratio in CD34+ cells of chronic myeloid leukemia patients does not predict treatment response. Leuk Lymphoma 2012;53:1627-1629.
21. Lucas C, Harris R, Giannoudis A, et al. BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia. Br J Haematol 2010;149:458-460.
22. Copland M, Hamilton A, Elrick L, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-4539.
23. Belloc F, Moreau-Gaudry F, Uhalde M, et al. Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines. Cancer Biol Ther 2007;6:912-919.
24. Hiwase DK, White DL, Powell JA, et al. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia 2010;24:771-778.
25. Konig H, Copland M, Chu S, et al. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 2008;68:9624-9633.
26. Okabe S, Tauchi T, Ohyashiki K. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells. Clin Cancer Res 2008;14:6181-6186.
27. Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications. Clin Cancer Res 2008;14:3881-3888.
28. Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 2004;104:3739-3745.
29. Kindler T, Breitenbuecher F, Kasper S, et al. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. Leukemia 2003;17:999-1009.
30. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368-2373.
31. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697-704.
32. Chen Y, Agarwal S, Shaik NM, et al. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther 2009;330:956-963.
33. Kuroda J, Puthalakath H, Cragg MS, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006;103:14907-14912.
34. Lipka DB, Wagner MC, Dziadosz M, et al. Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells. PLoS One 2012;7:e40853.